Peer Reviewed
Drug update

Biological therapies for rheumatoid arthritis: TNF inhibitors

John Hy Moi, Russell Rc Buchanan
Abstract
The advent of TNF inhibitors represents a significant advance in treatment options for patients with rheumatoid arthritis who are refractory to traditional DMARD therapy.
Key Points

    Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder of unknown aetiology. It is the most common form of inflammatory arthritis and affects about 0.5 to 1% of the adult population worldwide. The peak incidence of disease onset occurs in people aged between 20 and 40 years, with women representing three-quarters of all those diagnosed with the condition.

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?